胎盘绒毛延迟成熟与胎儿先天性心脏病相关
单中心回顾性队列研究纳入194例胎儿先天性心脏病妊娠和105例对照,采用阿姆斯特丹标准评估胎盘病理。先心病组胎盘绒毛延迟成熟(19% vs 6%,P<.001)和母体血管灌注不良(34% vs 19%,P=.007)发生率高于对照,胎儿血管灌注不良无显著差异。
要点
- 先心病组胎盘绒毛延迟成熟发生率19%,高于对照组的6%(P<.001)。
- 先心病组母体血管灌注不良发生率34%,高于对照组的19%(P=.007)。
- 胎儿血管灌注不良两组无显著差异(10% vs 6%,P=.23)。
核心结论
- 胎儿先天性心脏病妊娠的胎盘绒毛延迟成熟和母体血管灌注不良发生率高于对照,提示胎盘发育不良可能与母体因素有关。
- 未来需要进一步研究以确定这些异常与出生后婴儿结局的关联。
研究设计与样本
- 单中心回顾性队列研究,2013年1月至2019年6月。
- 纳入胎龄≥37周出生、产前诊断中重度先天性心脏病的婴儿194例,对照组为胎龄≥37周出生、无胎儿先天性心脏病或其他主要妊娠并发症的105例,按母亲种族和民族及婴儿性别匹配。
- 采用阿姆斯特丹标准将胎盘病理分为绒毛延迟成熟、母体血管灌注不良、胎儿血管灌注不良和炎症性病变。
主要发现
- 先心病组绒毛延迟成熟19% vs 对照组6%(P<.001)。
- 先心病组母体血管灌注不良34% vs 对照组19%(P=.007)。
- 两组胎儿血管灌注不良无显著差异(10% vs 6%,P=.23)。
- 与对照相比,2心室解剖的先心病婴儿绒毛延迟成熟比值比为5.5(95%CI 2.2-15.7,P<.01)。
- 2心室解剖婴儿母体血管灌注不良高2.2倍(P=.02),单心室生理伴肺动脉梗阻婴儿高2.9倍(P=.02)。
关键数值与推荐
- 绒毛延迟成熟:先心病组19% vs 对照组6%(P<.001)。
- 母体血管灌注不良:先心病组34% vs 对照组19%(P=.007)。
- 胎儿血管灌注不良:先心病组10% vs 对照组6%(P=.23)。
- 2心室解剖先心病婴儿绒毛延迟成熟比值比5.5(95%CI 2.2-15.7,P<.01)。
- 先心病组内,校正心脏诊断后,绒毛延迟成熟与婴儿出生头围的比值比1.2(95%CI 1.0-1.5,P=.02)及产房内婴儿呼吸支持的比值比3.0(95%CI 1.3-6.5,P=.007)持续相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The placenta is crucial for the overall development and lifelong health of the fetus. Abnormal placental development and function occur in pregnancies with fetal congenital heart disease. However, studies that use standardized diagnostic criteria and incorporate control populations are lacking. This limits the generalizability of current research and the ability to determine the specific placental abnormalities associated with congenital heart disease. OBJECTIVE: This study applied consensus statement guidelines (known as the Amsterdam criteria) for placental pathology interpretation to compare the frequency and pattern of abnormalities in pregnancies with fetal congenital heart disease to demographically matched control pregnancies and evaluate for differences in placental abnormalities by cardiac physiology. STUDY DESIGN: A single-center retrospective cohort study was conducted from January 2013 to June 2019. Infants with a prenatal diagnosis of moderate-severe congenital heart disease who were born at ≥37 weeks of gestation were included. A control group born at ≥37 weeks of gestation but without fetal congenital heart disease or other major pregnancy complications was matched to the congenital heart disease group on maternal race and ethnicity and infant sex. Using the Amsterdam criteria, placental pathology findings were categorized as delayed villous maturation, maternal vascular malperfusion, fetal vascular malperfusion, and inflammatory lesions. The frequency of placental abnormalities was compared between groups, and logistic regression was performed to evaluate the association of clinical and sociodemographic factors with delayed villous maturation, maternal vascular malperfusion, and fetal vascular malperfusion. RESULTS: There were 194 pregnancies with fetal congenital heart disease and 105 controls included, of whom 83% in the congenital heart disease group and 82% in the control group were of non-Hispanic White race and ethnicity. Compared with controls, pregnancies with fetal congenital heart disease had higher rates of delayed villous maturation (6% vs 19%; P<.001) and maternal vascular malperfusion (19% vs 34%; P=.007) but not fetal vascular malperfusion (6% vs 10%; P=.23). Infants with congenital heart disease with 2-ventricle anatomy displayed the highest odds of delayed villous maturation compared with controls (odds ratio, 5.5; 95% confidence interval, 2.2-15.7; P<.01). Maternal vascular malperfusion was 2.2 times higher (P=.02) for infants with 2-ventricle anatomy and 2.9 times higher (P=.02) for infants with single-ventricle physiology with pulmonic obstruction. Within the congenital heart disease group, delayed villous maturation was associated with higher maternal body mass index, polyhydramnios, larger infant birth head circumference, and infant respiratory support in the delivery room, whereas maternal vascular malperfusion was associated with oligohydramnios. In multivariable models adjusting for cardiac diagnosis, associations of delayed villous maturation persisted for infant birth head circumference (odds ratio, 1.2; 95% confidence interval, 1.0-1.5; P=.02) and infant respiratory support in the delivery room (odds ratio, 3.0; 95% confidence interval, 1.3-6.5; P=.007). CONCLUSION: Pregnancies with fetal congenital heart disease displayed higher rates of delayed villous maturation and maternal vascular malperfusion than controls, suggesting that placental maldevelopment may relate to maternal factors. Future investigations are needed to determine the association of these abnormalities with postnatal infant outcomes.
引用
- O'Hare CB, Mangin-Heimos KS, Gu H, et al. Placental delayed villous maturation is associated with fetal congenital heart disease. Am J Obstet Gynecol. 2022. PMID: 35985515. doi:10.1016/j.ajog.2022.08.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。